Rich Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, has retained the services of an Asian contract research organization CMIC Asia-Pacific, Pte. Ltd., to run Rich's upcoming Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. CMIC is considered to be one of Asia's top CRO's for running clinical oncology studies.
"We are very pleased to have retained the services of a well-respected and internationally recognized CRO which specializes in managing clinical studies," said Ben Chang, Chief Executive Officer of Rich. "After carefully evaluating many competing organizations, we have chosen this CRO based on their extensive experience in managing global clinical trials of medicines."